To compare perioperative, oncological, and survival outcomes of total gastrectomy (TG) versus subtotal gastrectomy (SG) in patients with locally advanced distal diffuse gastric adenocarcinoma treated with perioperative 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy. Diffuse distal gastric cancer is characterized by infiltrative growth patterns and early nodal metastasis. Whilst radical resection remains the cornerstone of curative treatment, the optimal extent of surgery with TG or SG, remains debated. This international multicenter cohort study analyzed data from patients with histologically confirmed diffuse gastric adenocarcinoma, located > 5 cm from the gastroesophageal junction. Endpoints included surgical margin status, nodal yield, perioperative morbidity, recurrence patterns, time-to-recurrence (TTR), and overall survival (OS). Outcomes were compared using multivariate analyses. In total, 188 (39.0
e13054 Background: The last decade has seen a rapid increase in systemic treatment options for patients with HR+ ABC. The incorporation of CDK4/6 inhibitors in first line (1L) is now standard practice leading to improved survival. However, there is a paucity of data on uptake of standard therapies and associated toxicities in the real-world setting. Methods: ARORA is a secondary data use study of Australian patients with HR+ ABC capturing prospective data on patient characteristics, systemic therapy sequencing and treatment outcomes in routine clinical practice. Patients aged > 18 diagnosed after 1 Jan 2020 are eligible. Results: Data from 294 patients at 16 sites was analysed with a median follow up of 15 months. Mean age was 63 years; 23% > 75 years. 64% were ECOG 0, 5.4% had a familial syndrome, 61% had relapsed metastatic disease and 19.4% had bone only metastases at diagnosis. Of patients who relapsed, 14.6% and 52.8% received neoadjuvant and adjuvant chemotherapy respectively, and 77.5% received adjuvant endocrine therapy (ET). 41% relapsed on or within 12 months of stopping adjuvant ET. 5 patients (1.7%) did not receive any systemic therapy for ABC. Of those on 1L therapy, 223 (77%) received CDK4/6i + ET, 38 (13.1%) received ET alone and 26 (9%) received chemotherapy. Choice of 1L CDK4/6i was palbociclib (50.7%), ribociclib (34.5%) and abemaciclib (9.9%). Patients who received 1L ET alone were older (mean age 75 vs 62 years; 68.4 vs 16.6% > 75 years) with poorer performance status (34.2 vs 6.3% ECOG ≥2) and more comorbidities (76.3 vs 36.8% Charlson index > 2) compared to those who received 1L CDK4/6i + ET. Conversely, those on 1L chemotherapy were younger (mean age 54, 96.2% < 75years), with better performance status (69.2% ECOG 0-1) and fewer comorbidities (88.5% Charlson index < 2). Patients receiving 1L chemotherapy were more likely to have visceral metastases compared to those on CDK4/6i + ET (69.2 vs 43.1%, p = 0.01). The most common reported toxicities in patients receiving CDK4/6i were diarrhea (59% abemaciclib vs 3.9% ribociclib vs 2.7% palbociclib), neutropenia (38.1% palbociclib vs 32.5% ribociclib vs 22.7% abemaciclib) and nausea/vomiting (27.3% abemaciclib vs 22.1% ribociclib vs 12.4% palbociclib). Abnormal LFTs occurred in 9.1% of patients on abemaciclib (vs 3.9% ribociclib and < 1% palbociclib). 2 patients (1.8%) on palbociclib had pneumonitis whilst 1 (1.3%) on ribociclib had QTc prolongation. Survival data is immature. Conclusions: Despite CDK4/6i + ET being gold standard treatment in 1L HR+ ABC, only 3/4 of patients received this combination, with a substantial minority receiving ET alone or chemotherapy. Age, ECOG status, comorbidity burden and presence of visceral disease appear to be major determinants of treatment choice. Toxicity profile of the CDK4/6i agents were mostly in line with clinical trial results, although longer follow up is needed to confirm this.
PROBLEM:Accessing professional support such as professional development, clinical supervision and peer support can be difficult for rural and regional allied health (AH) clinicians and may have a negative impact on workforce recruitment and retention. SETTING:The Loddon Mallee Health Network, a Health Service Partnership of 19 health services in North-Western Victoria. Professions included were AH therapy professions. KEY MEASURES FOR IMPROVEMENT:Five professional support and workforce capacity building strategies were implemented, relating to clinical supervision, building capacity to provide student placements, professional development, graduate support and building AH clinical educator capacity. Program logic was used as the overarching methodology to evaluate the implementation of these strategies. STRATEGIES FOR CHANGE:The project engaged AH managers, clinical educators and clinicians from across the region to collaboratively develop and implement the identified professional support strategies. EFFECTS OF CHANGE:Access to professional support and building the capacity of the workforce improved through shared approaches including the following: clinical supervision, professional shadowing and peer support for educators and shared student placements. LESSONS LEARNT:Benefits to using a regional approach to plan, deliver and evaluate professional support for AH were identified. Recommendations are made to inform collaborative approaches to professional support in regional settings.
ISSUE ADDRESSED:Tobacco use remains a leading cause of preventable illness and death. Hospital admissions offer a critical opportunity to support smoking cessation. Electronic patient record (ePR) systems can enable systematic identification and coordination of cessation care; however, clinician engagement with smoking-related ePR functionality is not well understood. This study examined smoking-related assessment and documentation practices, and determinants influencing use of the ePR for smoking cessation support in a regional Australian hospital. METHODS:A cross-sectional survey was distributed to clinicians working on inpatient wards. The survey assessed how often clinicians asked about smoking, what information they collected and documented, and clinicians' knowledge and use of ePR functionality to support cessation. Barriers and enablers were explored using the NASSS (Non-adoption, Abandonment, Scale-up, Spread, Sustainability) framework, which considers technology use across clinical, organisational and system levels. RESULTS:Of the 101 respondents, 93% reported routinely asking about smoking status. However, only 50% indicated that they knew how to identify smoking status within the ePR, and fewer than 20% reported confidence in using the system to assess nicotine dependence or provide structured cessation support. Only 6% had received relevant training. Reported barriers included lack of knowledge, limited training, low system usability and competing priorities within workflows. CONCLUSIONS:While most clinicians ask about smoking, effective use of the ePR to deliver comprehensive cessation support remains limited. SO WHAT?: Improving smoking cessation support in hospital settings requires more than clinician intent. Training, embedded decision support and better system integration are needed to close the gap between clinical opportunity and evidence-based care.